Chimeric cd4 monoclonal antibody cm-t412 as a therapeutic approach to rheumatoid arthritis

Authors

  • Peter A. VanDer Lubbe MD,

    Corresponding author
    1. Department of Rheumatology, University Hospital Leiden
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    • Department of Rheumatology, University Hospital, Building 1, C4-R, P.O. Box 9600, 2300 RC Leiden, The Netherlands
    Search for more papers by this author
  • Christian Reiter MD,

    1. Institute for Immunology, University of Munich
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author
  • Ferdinand C. Breedveld MD PhD,

    1. Professor of Rheumatology, Department of Rheumatology, University Hospital Leiden
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author
  • Klaus Kr¨ger MD,

    1. Department of Rheumatology, Medizinische Poliklinik, University of Munich
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author
  • Manfred Schattenkirchner MD,

    1. Professor of Medicine, Department of Rheumatology, Medizinische Poliklinik, University of Munich
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author
  • Martin E. Sanders Md Facp,

    1. Centocor Inc.
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author
  • Gert Riethm¨ller MD

    1. Professor of Medicine, Institute for Immunology, University of Munich
    2. Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; the Institute for Immunology and the Department of Rheumatology, Medizinische Poliklinik, University of Munich, Munich, Germany; and Centocor Inc., Malvern, Pennsylvania.
    Search for more papers by this author

Abstract

Objective. To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA).

Methods. Thirty-two RA patients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days.

Results. There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity.

Conclusion. Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RA patients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.

Ancillary